The enclosed prescription medication is made by ImprimisRx®, a pharmaceutical compounding company that specializes in customizing medications to meet unique patient and practitioner needs. This document is for professional use only. This document contains information related to the individual ingredients contained in the above described compounded formulation. Use of this formulation has not been reviewed by the U.S. Food and Drug Administration (FDA) for any indication. This information may not cover all possible uses, directions, side effects, precautions, allergic reactions or drug interactions. ImprimisRx dispenses compounded medicines to licensed practitioners and individually identified patients with valid prescriptions. Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound essentially copies of commercially available products. References available upon request.

Questions?
Contact us at:
(844) 446-6979

ImprimisRx
12264 El Camino Real, Suite 350
San Diego, CA 92130

imprimis Rx®

Product Name:

Dexpanthenol

Injection Solution

Dexpanthenol

Possible Indications	Is a sterile, nonpyrogenic, aqueous solution indicated for prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.
Possible Adverse Effects	There have been a few reports of allergic reactions and single reports of several other adverse events in association with the administration of Dexpanthenol. A causal relationship is uncertain. One patient experienced itching, tingling, difficulty in breathing. Another patient had red patches of skin. Two patients had generalized dermatitis and one patient urticaria. One patient experienced temporary respiratory difficulty following administration of Dexpanthenol injection 5 minutes after succinylcholine was discontinued. One patient experienced a noticeable but slight drop in blood pressure after administration of Dexpanthenol while in the recovery room. One patient experienced intestinal colic one-half hour after the drug was administered. Two patients vomited following administration and two patients had diarrhea IO days post-surgery and after Dexpanthenol Injection. One elderly patient became agitated after administration of the drug.
Potential Contraindications/ Precautions	If any signs of a hypersensitivity reaction appear, Dexpanthenol Injection should be discontinued. If ileus is a secondary consequence of mechanical obstruction, primary attention should be directed to the obstruction. The management of adynamic ileus includes the correction of any fluid and electrolyte imbalance (especially hypokalemia), anemia and hypoproteinemia, treatment of infection, avoidance where possible of drugs which are known to decrease gastrointestinal motility and decompression of the gastrointestinal tract when considerably distended by nasogastric suction or use of a long intestinal tube.
Storage	Store at 20° to 25°C (68° to 77°F); excursions permitted to I5° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).
Auxiliary Labeling	There have been rare instances of allergic reactions of unknown cause during the concomitant use of Dexpanthenol Injection with drugs such as antibiotics, narcotics and barbiturates. Dexpanthenol Injection should not be administered within one hour of succinylcholine.